03 November 2024
: Case report
Finerenone as a Novel Treatment for Gitelman Syndrome: A Case Study of a 35-Year-Old Male with Adrenal Mass and Hypokalemia
Challenging differential diagnosis, Rare disease, Adverse events of drug therapy
Rujie Jiang1ABCDEF, Qiue Liu1B, Yanan Sun1B, Xiaoqing Dai1C, Feng Xu1D*, Fang Wang1ADEFDOI: 10.12659/AJCR.944492
Am J Case Rep 2024; 25:e944492
Table 3. Treatment process and results.
Date | Treat | Serum potassium (mmol/L) | Serum magnesium (mmol/L) | Blood pressure (mmHg) |
---|---|---|---|---|
2019/07/09 | No treatment (first discovered) | 2.7 | 0.58 | 132/85 |
2019/07~2019/08 | potassium chloride 2000 mg tid | 2.8~3.35 | 0.4~0.6 | (128~134)/(76~87) |
2019/08~2019/10 | potassium chloride 500 mg bid+ magnesium chloride 1000 mg bid+ spironolactone 20 mg bid | 3.63~3.71 | 0.46~0.6 | (115~133)/(73~83) |
2019/10~2023/09 | potassium chloride 2000 mg tid+ magnesium chloride 1000 mg bid | 2.8~3.3 | 0.48~0.68 | (121~135)/(74~85) |
2023/09~ | potassium chloride 1500 mg bid+ magnesium chloride 1000 mg bid+ finerenone 10mg bid | 3.48~3.8 | 0.53~0.91 | (118~128)/(70~79) |